The Apollo Athenaa Cancer Conclave 2026 brought together leading national and international experts, healthcare professionals, and young oncologists for a comprehensive academic and clinical exchange focused on advancing cancer care. The conclave served as a dynamic platform for multidisciplinary collaboration, knowledge sharing, and innovation across the oncology spectrum.

A key highlight of the scientific program was the strong emphasis on precision oncology and personalized treatment approaches. Sessions explored biomarker-driven therapies, advances in immunotherapy, and evolving strategies for managing complex breast cancer subtypes, including triple-negative and hormone receptor–positive disease. Experts also discussed optimal sequencing of therapies, integration of genomic profiling, and the expanding role of targeted treatments in improving patient outcomes.

Surgical oncology discussions focused on the evolving paradigm of de-escalation, particularly in axillary management following neoadjuvant therapy. International perspectives reinforced the shift toward less invasive, evidence-based approaches that maintain clinical outcomes while significantly reducing treatment-related morbidity.